Novartis has entered into a strategic partnership with a local Contract Research Organization to enhance its clinical trial operations in Southeast Asia.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) is pleased to announce the formal establishment of two significant business divisions, each representing distinct aspects of the company's comprehensive product, service, and asset portfolio.

Twist Bioscience Corporation (NASDAQ: TWST) has unveiled a significant drug discovery partnership with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") aimed at the development of novel antibodies for treating autoimmune diseases.

Serina Therapeutics, Inc. (referred to as "Serina"), a clinical-stage biotechnology firm dedicated to developing therapies for Parkinson's Disease and other neurological disorders, has entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE), a publicly traded biotechnology company, on August 29, 2023.

Cybin Inc. a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, and Small

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company dedicated to advancing cancer treatment and prevention, has initiated the treatment of the third participant in collaboration with Moffitt Cancer Center as part of an ongoing clinical trial for its innovative chimeric antigen receptor T-cell (CAR-T) therapy designed for ovarian cancer.

Allucent, a prominent global mid-sized clinical research organization (CRO), has been designated by the Biomedical Advanced Research and Development Authority

Zhiyi Biotech has announced the initiation of the U.S. Phase 1 clinical trial for their innovative product SK10, which is aimed at addressing Chemotherapy-induced Diarrhea (CID). The trial marks a significant milestone as the first three subjects have been successfully dosed. SK10 is a heat-killed Bacteroides fragilis product developed by Zhiyi Biotech.

Altogen Labs, a preclinical Contract Research Organization (CRO) laboratory, has announced the successful validation of a comprehensive array of 10 lung cancer xenograft models.

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics for brain disorders, has successfully completed a second Phase 1 clinical trial assessing the safety and efficacy of ML-007, a novel M1/M4 muscarinic receptor agonist.